1,394 results on '"Armstrong, Annalee"'
Search Results
152. 'Forced into a virtual world': Takeda hunts for COVID's silver linings
153. 'Forced into a virtual world': Can the tech that kept pharma R&D going through the pandemic tackle trial diversity, too?
154. 'Forced into a virtual world': At Medidata, things got real quiet
155. Aprea's myeloid program iced by FDA while tricky adverse event profile is sorted out
156. Moderna is ready to spend billions in COVID-19 cash, and the famed biotech has sights set on gene editing
157. Moderna abandons mid-stage mRNA cancer asset in favor of similar triple-attack candidate
158. Marinus hands over EU rights for antiseizure med to Orion in $30M upfront deal
159. Lilly investors hungry for news on Alzheimer's drug get a clearer picture of Q4 FDA filing
160. Moderna's RSV vaccine catches the fast track on heels of Pfizer's leapfrog into the queue
161. CytoDyn catches SEC, DOJ scrutiny over public claims about COVID-19 drug's viability
162. Roivant ditches plan to reacquire Immunovant, putting up $200M investment instead
163. AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
164. IGM poaches Gilead cancer chief Takimoto at pivotal moment for both companies
165. Another day, another billion-dollar deal for PeptiDream, this time with Alnylam
166. Lilly adds on to biomarker bombardment in Alzheimer's with two new donanemab analyses
167. Denali's Hunter syndrome data fails to impress, but 'Aduhelm-lenient' FDA could still approve
168. Biogen takes $542M hit over 2 failed gene therapy trials as Aduhelm revenue trickles in
169. Novartis is about to start ringing up peers to join ambitious new diversity program
170. Sanofi-Regeneron find narrower population of former smokers for COPD drug after mid-stage trial fails overall goal
171. Biotech earnings arrive under cloud of Delta variant, but Q2 gene editing results still offer reason to celebrate
172. AbbVie, Roche top data transparency list, but more could be done to build trust in medical system: report
173. While FibroGen and AstraZeneca stumble, cheeky GSK drops competing data for anemia drug
174. Biogen's Aduhelm win opened up market frenzy for Alzheimer's-focused companies
175. FDA says Aduhelm approval fit accelerated pathway to a T, as families begged for a shot to halt Alzheimer's decline
176. Hepion's NASH drug ready for phase 2b after clearing safety bar, dropping efficacy breadcrumbs
177. Ovid staff shuffle reads like a who's who of Big Pharma as biotech pivots from Angelman failure
178. 'Data mining' and 'p-value hacking': Cel-Sci CEO tries to spin cancer trial failure into a win
179. Moderna's first seasonal flu vaccine slides into clinic as pharma giants crowd into mRNA
180. Fierce15 winner Rallybio establishes proof-of-concept in phase 1/2 study for rare fetal bleeding disorder
181. Arrowhead slams brakes on early-stage cystic fibrosis study after rat study triggers lung inflammation concerns
182. Novavax pledges to help verify COVID vaccine status for trial participants as the world opens back up to travel
183. 'Only 13 calls to make': a Q&A with executive search firm partner Darren Raycroft on diversity in the biotech C-suite
184. Intellia hits a 'home run' with gene editing results, setting up entire field for a grand slam
185. FDA's renewed focus on oncology dosing spooks investors, but companies say they're ready
186. With first-in-human trial results, Intellia shows the world that gene editing has arrived
187. Corbus tries to shift focus to early-stage pipeline as autoimmune treatment flunks another trial
188. 'Let the games begin': Reinvigorated Alzheimer's pipeline breaches the levee with planned Lilly filing, Bristol Myers opt-in
189. Biden officials aim for the stars with new NIH research arm to push bold, risky biomedical ideas
190. Alchemab's new well-connected CEO will lead biotech on journey to address hard-to-treat diseases
191. Backed by Boehringer Ingelheim fund, Nuevocor snags $24M to tackle diseased hearts with gene therapy
192. Diversity initiatives pick up across biotech industry, but women, people of color still lack representation
193. Biogen-Sage depression drug hits main goal of improving symptoms, then it gets complicated
194. Yet another failure in Biogen's gene therapy program leaves no dent in stock price in wake of Aduhelm approval
195. J&J's Burton grabs hold of Moderna rocket ship as the vaccine developer's next chief medical officer
196. Humanigen angling to go from zero to $1B with U.S., U.K. COVID-19 therapy filings
197. Bayer's billon-dollar Parkinson's disease bets land in the clinic
198. FDA's 'intellectually insulting' aducanumab decision opens up a regulatory foothold for leading competitors
199. Novartis rolls out encouraging phase 2 data in rare kidney diseases with little competition in sight
200. ASCO: Amgen deals 'knockdown punch' with Lumakras approval, but decades of work lie ahead
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.